OKYO Pharma Ltd is a Guernsey clinical-stage issuer that has compressed a dry-eye-to-neuropathic-corneal-pain pivot, a leadership rebuild, and a Type D agency alignment into one Phase 3 option. The equity story is no longer about whether urcosimod can generate a signal in a specialist clinic. The story is whether an eighteen-patient, single-site, early-unmasked Phase 2 package plus Fast Track status is enough for a one-hundred-eleven-patient global trial to carry a registration file. Management frames the February capital raise as sufficient to finish that trial. The market is treating the claim as provisional rather than settled.
The February underwritten sale priced ordinary shares at $1.85. That raise, with the overallotment, produced about $22 million of gross proceeds. Year-end cash sat near $21 million. That cash is the entire funding claim for NEPTUNE, the Neuropathic Eye Pain Treatment with Urcosimod and Nerve Evaluation study. Historical operating spend last year was closer to a mid-single-digit million burn, which is why the cash looks ample on a trailing basis. A multicenter Phase 3 in the United States and Europe is a different cost object than an eighteen-patient Tufts protocol. The tension is that the runway statement is a management projection, not an audited trial budget.
The Type D meeting in early July is the event that changed the calendar. OKYO is now selling a single-dose, two-to-one randomization design as a potential single-trial path, and is preparing a Breakthrough Therapy request on the back of that feedback. The counterargument is methodological: the Phase 2 closed early so the company could unmask, and a pain-scale win in a tiny Tufts cohort does not automatically survive a multicenter European and United States sample. Does NEPTUNE actually start in the second half of the year, and does the agency keep treating one trial as enough?